Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
Status:
RECRUITING
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and obesity.
Phase:
PHASE2
Details
Lead Sponsor:
Yale University
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Novo Nordisk A/S